vs
Acadian Asset Management Inc.（AAMI）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Acadian Asset Management Inc.的1.2倍（$199.9M vs $172.2M），Acadian Asset Management Inc.净利率更高（20.2% vs -29.5%，领先49.6%），Acadian Asset Management Inc.同比增速更快（2.6% vs -5.9%），过去两年Acadian Asset Management Inc.的营收复合增速更高（27.6% vs 7.7%）
Acadian Asset Management Inc.是一家总部位于美国马萨诸塞州波士顿的资产管理机构，专注于为全球机构及个人客户提供专业的投资管理解决方案，在资产管理领域拥有成熟的服务经验与市场布局。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AAMI vs APLS — 直观对比
营收规模更大
APLS
是对方的1.2倍
$172.2M
营收增速更快
AAMI
高出8.6%
-5.9%
净利率更高
AAMI
高出49.6%
-29.5%
两年增速更快
AAMI
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $172.2M | $199.9M |
| 净利润 | $34.7M | $-59.0M |
| 毛利率 | — | — |
| 营业利润率 | 33.3% | -25.6% |
| 净利率 | 20.2% | -29.5% |
| 营收同比 | 2.6% | -5.9% |
| 净利润同比 | -18.4% | -62.2% |
| 每股收益（稀释后） | $0.97 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AAMIAPLS
| Q4 25 | $172.2M | $199.9M | ||
| Q3 25 | $144.2M | $458.6M | ||
| Q2 25 | $127.4M | $178.5M | ||
| Q1 25 | $119.9M | $166.8M | ||
| Q4 24 | $167.8M | $212.5M | ||
| Q3 24 | $123.1M | $196.8M | ||
| Q2 24 | $109.0M | $199.7M | ||
| Q1 24 | $105.7M | $172.3M |
净利润AAMIAPLS
| Q4 25 | $34.7M | $-59.0M | ||
| Q3 25 | $15.1M | $215.7M | ||
| Q2 25 | $10.1M | $-42.2M | ||
| Q1 25 | $20.1M | $-92.2M | ||
| Q4 24 | $42.5M | $-36.4M | ||
| Q3 24 | $16.9M | $-57.4M | ||
| Q2 24 | $11.0M | $-37.7M | ||
| Q1 24 | $14.6M | $-66.4M |
营业利润率AAMIAPLS
| Q4 25 | 33.3% | -25.6% | ||
| Q3 25 | 18.4% | 48.7% | ||
| Q2 25 | 12.7% | -18.6% | ||
| Q1 25 | 26.6% | -50.0% | ||
| Q4 24 | 38.7% | -12.3% | ||
| Q3 24 | 21.9% | -24.0% | ||
| Q2 24 | 18.9% | -14.7% | ||
| Q1 24 | 21.7% | -36.0% |
净利率AAMIAPLS
| Q4 25 | 20.2% | -29.5% | ||
| Q3 25 | 10.5% | 47.0% | ||
| Q2 25 | 7.9% | -23.6% | ||
| Q1 25 | 16.8% | -55.3% | ||
| Q4 24 | 25.3% | -17.1% | ||
| Q3 24 | 13.7% | -29.2% | ||
| Q2 24 | 10.1% | -18.9% | ||
| Q1 24 | 13.8% | -38.5% |
每股收益（稀释后）AAMIAPLS
| Q4 25 | $0.97 | $-0.40 | ||
| Q3 25 | $0.42 | $1.67 | ||
| Q2 25 | $0.28 | $-0.33 | ||
| Q1 25 | $0.54 | $-0.74 | ||
| Q4 24 | $1.11 | $-0.30 | ||
| Q3 24 | $0.45 | $-0.46 | ||
| Q2 24 | $0.29 | $-0.30 | ||
| Q1 24 | $0.37 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $466.2M |
| 总债务越低越好 | $200.0M | — |
| 股东权益账面价值 | — | $370.1M |
| 总资产 | $677.0M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AAMIAPLS
| Q4 25 | — | $466.2M | ||
| Q3 25 | — | $479.2M | ||
| Q2 25 | — | $370.0M | ||
| Q1 25 | — | $358.4M | ||
| Q4 24 | — | $411.3M | ||
| Q3 24 | — | $396.9M | ||
| Q2 24 | — | $360.1M | ||
| Q1 24 | — | $325.9M |
总债务AAMIAPLS
| Q4 25 | $200.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $275.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $93.1M |
股东权益AAMIAPLS
| Q4 25 | — | $370.1M | ||
| Q3 25 | — | $401.2M | ||
| Q2 25 | — | $156.3M | ||
| Q1 25 | — | $164.2M | ||
| Q4 24 | — | $228.5M | ||
| Q3 24 | — | $237.1M | ||
| Q2 24 | — | $264.3M | ||
| Q1 24 | — | $266.7M |
总资产AAMIAPLS
| Q4 25 | $677.0M | $1.1B | ||
| Q3 25 | $751.4M | $1.1B | ||
| Q2 25 | $672.3M | $821.4M | ||
| Q1 25 | $677.3M | $807.3M | ||
| Q4 24 | $703.2M | $885.1M | ||
| Q3 24 | $555.2M | $901.9M | ||
| Q2 24 | $533.1M | $904.5M | ||
| Q1 24 | $544.9M | $831.9M |
负债/权益比AAMIAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.4M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-14.3M |
| 自由现金流率自由现金流/营收 | — | -7.1% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | -0.07× | — |
| 过去12个月自由现金流最近4个季度 | — | $45.0M |
8季度趋势，按日历期对齐
经营现金流AAMIAPLS
| Q4 25 | $-2.4M | $-14.2M | ||
| Q3 25 | $-23.9M | $108.5M | ||
| Q2 25 | $61.6M | $4.4M | ||
| Q1 25 | $-48.8M | $-53.4M | ||
| Q4 24 | $55.8M | $19.4M | ||
| Q3 24 | $69.6M | $34.1M | ||
| Q2 24 | $45.7M | $-8.3M | ||
| Q1 24 | $-40.4M | $-133.0M |
自由现金流AAMIAPLS
| Q4 25 | — | $-14.3M | ||
| Q3 25 | — | $108.3M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $-53.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-8.4M | ||
| Q1 24 | — | $-133.3M |
自由现金流率AAMIAPLS
| Q4 25 | — | -7.1% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | -32.0% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -4.2% | ||
| Q1 24 | — | -77.3% |
资本支出强度AAMIAPLS
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.2% |
现金转化率AAMIAPLS
| Q4 25 | -0.07× | — | ||
| Q3 25 | -1.58× | 0.50× | ||
| Q2 25 | 6.10× | — | ||
| Q1 25 | -2.43× | — | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | 4.12× | — | ||
| Q2 24 | 4.15× | — | ||
| Q1 24 | -2.77× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AAMI
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
